Literature DB >> 33988738

Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Xia Qin1, Yi-Ping Zhu2, Cheng-Juan Luo1, Ming Zhou3, Ke Huang4, Chun Chen4, Wei-Ping Zhang5, Yuan Sun6, Rong-Mu Luo7, Xiang-Feng Tang8, Ting Yang9, Xian-Min Song10, Shao-Yan Hu11, Zi-Min Sun12, Jiong Hu13, Shun-Qing Wang14, Jing Chen15.   

Abstract

With the dramatic improvements in outcomes following alternative donor hematopoietic stem cell transplantation (HSCT), interest in the use of alternative donors in severe aplastic anemia (SAA) is increasing. We conducted a multicenter prospective study to explore the efficiency and safety of upfront HSCT from a 6-8/8 HLA-matched unrelated donor (MUD) or 6-7/8 HLA-matched related donor (MRD) in acquired SAA patients under 40 years. Between August 2014 and July 2017, 115 patients were enrolled, including 48 (41.7%) patients receiving grafts from an 8/8 MUD, 25 (21.7%) from a 6-7/8 MRD, and 42 (36.5%) from a 6-7/8 MUD. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was higher in the 6-7/8 MUD group than in the 8/8 MUD group (42.9% vs. 12.8%, P=0.001). The corresponding incidence in the 6-7/8 MRD group was comparable to that in the 8/8 MUD group (21.7% vs. 12.8%, P=0.332). There was no significant difference in the incidence of chronic GVHD (24.3%, 13.6%, and 17.9%, P=0.676), graft failure (2.4%, 8.0%, and 6.3%, P=0.551), overall survival (85.7%, 96.0%, and 87.5%, P=0.424), and failure-free survival (83.3%, 88.0%, and 83.3%, P=0.885) among the three groups (6-7/8 MUD, 6-7/8 MRD, and 8/8 MUD). In multivariate analysis, conditioning regimen without low-dose irradiation or busulfan was associated with an inferior failure-free survival (HR=2.973, P=0.042). In conclusion, after an intensified conditioning regimen with additional low-dose irradiation or busulfan, the outcome of HSCT from a 6-7/8 MRD or 6-7/8 MUD is comparable to that from an 8/8 MUD.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Alternative donor; Aplastic anemia; Conditioning regimen

Year:  2021        PMID: 33988738     DOI: 10.1007/s00277-021-04540-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  37 in total

1.  Guidelines for the diagnosis and management of adult aplastic anaemia.

Authors:  Sally B Killick; Nick Bown; Jamie Cavenagh; Inderjeet Dokal; Theodora Foukaneli; Anita Hill; Peter Hillmen; Robin Ireland; Austin Kulasekararaj; Ghulam Mufti; John A Snowden; Sujith Samarasinghe; Anna Wood; Judith C W Marsh
Journal:  Br J Haematol       Date:  2015-11-16       Impact factor: 6.998

2.  First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.

Authors:  Andrea Bacigalupo; Rosi Oneto; Hubert Schrezenmeier; Britta Hochsmann; Carlo Dufour; Seiji Kojima; Xiaofan Zhu; Xiaojuan Chen; Surapol Issaragrisil; Suporn Chuncharunee; Dae Chul Jeong; Sabrina Giammarco; Maria Teresa Van Lint; Yizhou Zheng; Carlos Vallejo
Journal:  Am J Hematol       Date:  2018-07-23       Impact factor: 10.047

3.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.

Authors:  Danielle M Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie Desierto; Harshraj Leuva; Margaret Bevans; Colin Wu; Andre Larochelle; Katherine R Calvo; Cynthia E Dunbar; Neal S Young
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

Review 4.  How I treat acquired aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

5.  A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  André Tichelli; Hubert Schrezenmeier; Gérard Socié; Judith Marsh; Andrea Bacigalupo; Ulrich Dührsen; Anke Franzke; Michael Hallek; Eckhard Thiel; Martin Wilhelm; Britta Höchsmann; Alain Barrois; Kim Champion; Jakob R Passweg
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

6.  Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.

Authors:  Judith C Marsh; Andrea Bacigalupo; Hubert Schrezenmeier; Andre Tichelli; Antonio M Risitano; Jakob R Passweg; Sally B Killick; Alan J Warren; Theodora Foukaneli; Mahmoud Aljurf; H A Al-Zahrani; Britta Höchsmann; Philip Schafhausen; Alexander Roth; Anke Franzke; Tim H Brummendorf; Carlo Dufour; Rosi Oneto; Philip Sedgwick; Alain Barrois; Shahram Kordasti; Modupe O Elebute; Ghulam J Mufti; Gerard Socie
Journal:  Blood       Date:  2012-04-27       Impact factor: 22.113

Review 7.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

8.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

Authors:  G Socié; M Henry-Amar; A Bacigalupo; J Hows; A Tichelli; P Ljungman; S R McCann; N Frickhofen; E Van't Veer-Korthof; E Gluckman
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245

9.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

10.  Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia.

Authors:  Phillip Scheinberg; Olga Rios; Priscila Scheinberg; Barbara Weinstein; Colin O Wu; Neal S Young
Journal:  Am J Hematol       Date:  2014-06       Impact factor: 10.047

View more
  2 in total

1.  Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.

Authors:  Lan-Ping Xu; Zheng-Li Xu; Yuan-Yuan Zhang; Yi-Fei Cheng; Xiao-Dong Mo; Ting-Ting Han; Feng-Rong Wang; Chen-Hua Yan; Yu-Qian Sun; Yu-Hong Chen; Fei-Fei Tang; Wei Han; Yu Wang; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Bone Marrow Transplant       Date:  2022-05-04       Impact factor: 5.174

2.  Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia.

Authors:  Meijie He; Ruirui Gui; Yingling Zu; Zhen Li; Dao Wang; Yanna Mao; Xianjing Wang; Huili Wang; Yongping Song; Jian Zhou
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.